We began supporting BiPER Therapeutics at the very start of their fundraising journey, at the preclinical stage. Since then, we have continuously helped refine their materials and provided ongoing support for their investor communications.
Pitch Deck
Video
Website
Pitch deck adaptation, 2022
The pitch deck was enriched with visuals, upgraded, and restructured to clearly present complex scientific and clinical data as a concise, investor-ready narrative.
The redesigned deck supports fundraising and partner discussions by translating detailed research results into a clear and compelling visual story.

Investor-facing video 2022
By using a combination of 2D and 3D we showed selective ligands of BiP that lead to cancer cell death through strong ER Stress induction. BPR001 triggers cell death selectively in Cancer cells through apoptosis and autophagy.
By using simple but instructive infographic we demonstrated the results that the drug showed during preclinical development. Next, we showed the regression of various gastrointestinal cancers as the main effect of the drug.
Video Update, 2025
The video was created to clearly communicate the mechanism of action of BiP/GRP78 inhibition in cancer. To enhance scientific depth, key 2D elements were replaced with 3D visuals, allowing complex ER stress–related processes to be presented in a more precise and engaging way for investors and partners.
Website Update, 2025
Considering a website is essentially your 24/7 communication asset, keeping it fresh and up-to-date is incredibly important. To help BiPER make the best possible impression around the clock, we gave their website a complete, modern update.
This is how the website looked originally:
And here is the fresh redesign, featuring beautiful custom assets:
"The newly developed comms assets contributed to BiPER Therapeutics fundraising rounds and enables BiPER Tx making the difference in world-classs high level awards Boston Biotech Summit Galien Fondation Price and World Health expo Start-up pitch competition.
I decided to try working with Nanobot and was not disappointed. I was impressed by their systematic approach and the results I received, and I look forward to continuing our collaboration with this company.
Thank you for your patience and the great job."

Mehdi Chelbi
CEO & Co-Founder BIPER Therapeutics
